Buy acomplia online, order cheap acomplia

Product Description

What is Acomplia?

Acomplia (Rimonabant) is considered to be a representative of a new class of therapeutic agents that are referred to as CB1 blockers (Cannabinoid-1 Receptor Blockers). Acomplia helps to treat obesity and associated conditions.

Product Mechanism

Acomplia is known to be an inhibitor (selectively) of CB1 receptors that are found in peripheral organs and in the brain. These receptors are essential in lipid/fat and glucose metabolism (including the liver, adipose tissue, muscles and gastrointestinal tract). Acomplia acts by switching off the brain circles that cause hunger while smoking cannabis. Once CB1 receptors are blocked, excessive activity of EC system (endocannabinoid system) is decreased. The endocannabinoid system is considered to be a physiological system which includes certain receptors (eg., CB1 receptor). Moreover, this system regulates weight and controls balance of energy, lipid/fat and glucose metabolic processes. Acomplia helps to balance the activity of the endocannabinoid system and improves hunger cravings

Acomplia Usage

One should combine using of Acomplia with diet and exercise. In such a way the medication treats overweight or obese patients who suffer from irregular fat levels in the blood and Type Two diabetes. Acomplia is believed to prevent the risk of cardiovascular disease as well. Taking the drug will be advantageous especially for patients who suffer from considerable waist circumference - 102 cm (men) / 88 cm (women).

Can Acomplia help to quit smoking?

According to one-year studies of Sanofi-Aventis, Acomplia has shown itself as effective medicine in treatment of smoking in over 6,500 patients who were motivated to do it. A New Drug Application was submitted to FDA by Sanofi-Aventis. Afterwards, FDA issued a non-approvable letter for Acomplia usage in smoking cessation. However, an approvable letter was issued for this medication for use in overweight/obesity treatment. Acomplia has recently been allowed in the European Union. Is this medicine allowed in the United States? No. Sanofi-Aventis is waiting for the United States marketing go-ahead approval. The approval can be got by the end of this year. Sanofi-Aventis was asked to provide the United States health authorities with more information on this drug. European Union marketing approval of Acomplia was received in 2006 (June). According to Sanofi-Aventis, the first launch will take place in Britain in July. Afterwards, it will be followed by serious of launches in Finland, Denmark, Germany, Norway and Ireland in the 2nd half of this year.

What were the results of Clinical trial studies of Acomplia?

Clinical trial studies revealed that Acomplia could improve a large range of cardiometabolic risk factors. Besides, it promoted considerable weight loss. Just about 50 percent of the observed improvement in HbA1C (an indicator of blood sugar control), HDL-cholesterol and triglycerides was more than expected weight loss alone in those patients who used Acomplia.

What are the side-effects of this medicine?

The possible side effects of taking Acomplia may include nausea and vomiting. Because of these side effects, approximately 19 % of patients were forced to leave the trial on Acomplia versus 13 % of those people who got placebo.

Buy acomplia online - order cheap acomplia